Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis

Sponsor
University of Birmingham
Study ID
NCT01237119
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to investigate whether 48 weeks treatment with once-daily injections of liraglutide improves liver disease (liver fat, inflammation and scarring) and related metabolic parameters in overweight patients with nonalcoholic steatohepatitis, enough to warrant further investigation.

Key Dates

Start date
Aug 31, 2010
Status verified
Mar 2016
Primary completion
Jul 31, 2014
Completion
Jul 31, 2014

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
    A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
  • Placebo Comparator: Placebo
    Liraglutide-Placebo manufactured by Novo Nordisk.

Primary Outcome Measure

Liver Histological improvement [ Time Frame: 48 weeks ]

Related Studies